-
Staging is a common concept within cancer research that helps doctors determine the severity and track the progression of the disease. When it comes to multiple myeloma, a type of blood cancer, there are two primary staging models used to follow its development: the Durie-Salmon staging system and the International Staging...
-
Multiple Myeloma is a cancer which develops in the plasma cells of bone marrow. Plasma cells are a type of white blood cell responsible for the production of antibodies which target and attack germs found within the body. However, when cancer develops inside of a plasma cell, the cell...
-
Multiple myeloma is a type of cancer which forms inside of blood plasma cells. These cells are normally responsible for helping the body fight off infection by producing antibodies. Antibodies will track down and destroy any foreign bacteria which find their way into the blood, preventing illness. However,...
-
Multiple Myeloma is a type of cancer which can be found in the plasma cells of bone marrow. These cells are responsible for producing antibodies which help the body fight infection. However, when a plasma cell begins to behave abnormally and undergoes a change, it may begin to...
-
Multiple Myeloma is a type of cancer that affects plasma cells. These cells are present in bone marrow – the soft tissue which is found on the inside of bones. When the plasma cells become infected, they begin to duplicate aggressively, forming a tumor which can damage bones...
-
Multiple myeloma is a form of cancer that targets plasma cells (a type of white blood cell). Plasma cells create disease-fighting antibodies to carry out their responsibility of eliminating infections. Multiple myeloma may be asymptomatic in its early stages. If you show any multiple myeloma signs and symptoms, there...
-
There are currently more advanced, newer medications that are preferred over standard chemotherapy drugs in the treatment of multiple myeloma. According to the Multiple Myeloma Research Foundation, these drugs–proteasome inhibitors and immunomodulating agents–are known as novel agents. These medications have quickly become the standard for multiple myeloma treatment. Understanding...
-
There are numerous drug families used in the treatment of multiple myeloma. Patients may be either prescribed one type of medication on its own or in conjunction with other medications. One of the most commonly preferred drug families used in the treatment of multiple myeloma is known as proteasome...
-
When a patient is diagnosed with multiple myeloma, their healthcare team goes through all therapy options with them depending on their particular case. There are mainly two approaches to the treatment of multiple myeloma: local therapies or systemic medications. Local therapies such as radiation therapy or surgery entail targeting...
-
Produced by Janssen Biotech and Genmab, Darzalex™ or daratumumab is the first monoclonal antibody that was approved by the FDA for treating individuals with multiple myeloma. Antibodies are proteins produced by the immune system to defend the body against infections. Antibodies that are created in the lab (monoclonal antibodies)...
-
A relapsed myeloma—also known as a recurrent myeloma—is when a cancer mass regrows after treatment. A relapse may also occur while a patient is in remission. Since multiple myeloma does not have a cure, it is likely that, at some point in time, a patient will relapse. When a patient...
-
Patients with advanced multiple myeloma (MM) whose disease has worsened after multiple lines of therapy have a poor prognosis and very few treatment options available to them. The median survival time for these patients is nine months. The combination of () and low-dose may help some patients if their...
Staging is a common concept within cancer research that helps doctors determine the severity and track the progression of the disease. When it comes to multiple myeloma, a type of blood cancer, there are two primary staging models used to follow its development: the Durie-Salmon staging system and the International Staging...
Multiple Myeloma is a cancer which develops in the plasma cells of bone marrow. Plasma cells are a type of white blood cell responsible for the production of antibodies which target and attack germs found within the body. However, when cancer develops inside of a plasma cell, the cell...
Multiple myeloma is a type of cancer which forms inside of blood plasma cells. These cells are normally responsible for helping the body fight off infection by producing antibodies. Antibodies will track down and destroy any foreign bacteria which find their way into the blood, preventing illness. However,...
Multiple Myeloma is a type of cancer which can be found in the plasma cells of bone marrow. These cells are responsible for producing antibodies which help the body fight infection. However, when a plasma cell begins to behave abnormally and undergoes a change, it may begin to...
Multiple Myeloma is a type of cancer that affects plasma cells. These cells are present in bone marrow – the soft tissue which is found on the inside of bones. When the plasma cells become infected, they begin to duplicate aggressively, forming a tumor which can damage bones...
Multiple myeloma is a form of cancer that targets plasma cells (a type of white blood cell). Plasma cells create disease-fighting antibodies to carry out their responsibility of eliminating infections. Multiple myeloma may be asymptomatic in its early stages. If you show any multiple myeloma signs and symptoms, there...
There are currently more advanced, newer medications that are preferred over standard chemotherapy drugs in the treatment of multiple myeloma. According to the Multiple Myeloma Research Foundation, these drugs–proteasome inhibitors and immunomodulating agents–are known as novel agents. These medications have quickly become the standard for multiple myeloma treatment. Understanding...
There are numerous drug families used in the treatment of multiple myeloma. Patients may be either prescribed one type of medication on its own or in conjunction with other medications. One of the most commonly preferred drug families used in the treatment of multiple myeloma is known as proteasome...
Produced by Janssen Biotech and Genmab, Darzalex™ or daratumumab is the first monoclonal antibody that was approved by the FDA for treating individuals with multiple myeloma. Antibodies are proteins produced by the immune system to defend the body against infections. Antibodies that are created in the lab (monoclonal antibodies)...
A relapsed myeloma—also known as a recurrent myeloma—is when a cancer mass regrows after treatment. A relapse may also occur while a patient is in remission. Since multiple myeloma does not have a cure, it is likely that, at some point in time, a patient will relapse. When a patient...
Patients with advanced multiple myeloma (MM) whose disease has worsened after multiple lines of therapy have a poor prognosis and very few treatment options available to them. The median survival time for these patients is nine months. The combination of () and low-dose may help some patients if their...